ANAndreas Wiggers Nielsen

Andreas Wiggers Nielsen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Andreas Wiggers Nielsen has a total of 79 co-authors. Here are the top co-authors by number of shared publications:

  • Ellen-Margrethe Hauge

    Department of Rheumatology, Aarhus University Hospital, Led- Og Bindevævssygdomme, Aarhus, Denmark

    7 shared publications
  • Kresten Krarup Keller

    Department of Rheumatology, Aarhus University Hospital, Led- Og Bindevævssygdomme, Aarhus, Denmark

    6 shared publications
  • Lars Christian Gormsen

    Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

    6 shared publications
  • Christian Møller Sørensen

    Department of Internal Medicine, Horsens Regional Hospital , Horsens

    5 shared publications
  • Ib Tønder Hansen

    Department of Rheumatology, Aarhus University Hospital , Aarhus

    5 shared publications
  • Jesper Blegvad-Nissen

    Diagnostic Centre, Silkeborg Regional Hospital , Silkeborg

    5 shared publications

Latest Publications

  • Rheumatologist assessment in established polymyalgia rheumatica

    by Elisabeth Lindrup Nielsen, Agnete Overgaard Donskov, Christoffer Søvsø Våben, Andreas Wiggers Nielsen, Line Lier Frølund, Ib Tønder Hansen, Line Thorndal Moll, Berit Dalsgaard Nielsen, Christoffer Mørk, Ellen-Margrethe Hauge, et al.

    Objectives: Patients with established polymyalgia rheumatica (PMR) are often referred from general practitioners (GPs) to rheumatologists. This single-centre cohort study examined the frequency, indications and diagnostic outcomes of patients with established PMR referred to a rheumatology outpatient clinic after initial diagnosis by GPs or rheumatologists in a hospital outpatient setting. Methods: This single-centre retrospective cohort study included patients with established PMR referred to a department of rheumatology (2018–2024). Data from patient records covered time of referral, PMR diagnosis, discharge, re-referral, and indication for and outcome of rheumatologist assessment of patients with established PMR. Symptoms and clinical findings were also documented. Results: Among 237 patients diagnosed by rheumatologists, 52/204 (26%) of discharged patients were re-referred. They had shorter time from diagnosis to discharge than those not re-referred (median: 41 days vs 230 days, P < 0.01). Referrals of the 98 patients diagnosed by GPs were more often prompted by uncertainty about their primary diagnosis of PMR (51% vs 14%, P < 0.01), and less frequently by relapse (27% vs 50%, P < 0.01) or recurrence (11% vs 31%, P < 0.01) compared with patients diagnosed by rheumatologists. The PMR diagnosis was less frequently maintained in patients diagnosed by GPs compared with patients diagnosed by rheumatologists (62% vs 83%, P < 0.05). Conclusion: Re-referral was common among patients with established PMR, and the risk increased with discharge shortly after PMR diagnosis. The diagnosis was revised in one-third of patients diagnosed by GPs, highlighting diagnostic challenges and supporting referral of individuals suspected of PMR consistent with current recommendations.


  • Repeated short corticotropin testing in patients with polymyalgia rheumatica

    by Tobias Gaster, Andreas Wiggers Nielsen, Simon Bøggild Hansen, Agnete Overgaard Donskov, Marc K Nielsen, Ib Tønder Hansen, Berit Dalsgaard Nielsen, Søren Geill Kjær, Jesper Blegvad-Nissen, Christian Møller Sørensen, et al.

    Objective: To investigate adrenal function and the prevalence of glucocorticoid (GC) induced adrenal insufficiency (GIAI) in patients with polymyalgia rheumatica (PMR), the first 18 months after diagnosis. Methods: Newly diagnosed patients with PMR underwent short corticotropin tests before commencement of GC treatment and after 10 weeks, 6 months, and 12 months. Patients still on GC or with GIAI after 12 months were invited to a test after 18 months. GIAI was defined as a stimulated serum cortisol level <420 nmol/l. Results: : Sixty patients with PMR were enrolled. The mean (S.D.) stimulated cortisol levels declined significantly between baseline (678 ± 95) and month 6 (491 ± 114), followed by an increase at month 12 (549 ± 100). An inverse relationship was found between stimulated cortisol levels and current GC dose (P < 0.001). The proportion of GIAI peaked at month 6 (13/53, 25%) when all patients received GC. By 12 months, adrenal function had recovered in 12/13 (92%) of these patients. At month 12 and month 18, GIAI was present in 1/31 (3%) and 0/12 (0%), who were no longer receiving GC. Conclusion: Stimulated serum cortisol levels in patients with PMR did not reach pretreatment levels after cessation of GC treatment. GIAI was frequent but reversible during GC treatment for PMR, which supports the concept of increased GC dosing during stress in these patients. Implementation of routine use of the short corticotropin test for the diagnosis of GIAI after planned cessation of GC treatment in PMR is not justified by our data. Trial registration: Clinicaltrials.gov, http://clinicaltrials.gov, NCT04519580.


  • Open Access

    Whole-body and site specific [18F]FDG uptake patterns on PET/CT have limited value in differentiating between polymyalgia rheumatica and other inflammatory diseases: two cohorts of treatment-naïve suspected polymyalgia rheumatica

    by Andreas Wiggers Nielsen, Gijs D. van Praagh, Kornelis S. M. van der Geest, Ib Tønder Hansen, Berit Dalsgaard Nielsen, Søren Geill Kjær, Jesper Blegvad-Nissen, Kate Rewers, Christian Møller Sørensen, Elisabeth Brouwer, et al.

    It has been hypothesized that 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG) positron emission tomography (PET) computed tomography (CT) can distinguish polymyalgia rheumatica (PMR) from non-PMR patients based on the [18F]FDG-uptake patterns. Nevertheless, a comprehensive assessment of whole-body [18F]FDG-patterns across all uptaking musculoskeletal sites, as well as site-specific [18F]FDG-uptake patterns, has not been conducted. Therefore, this study aimed to investigate both the overall whole-body [18F]FDG-uptake patterns and the specific uptake patterns at individual sites in patients suspected of having PMR. Two distinct cohorts of patients with suspected PMR from Denmark and the Netherlands were prospectively included, encompassing 66/27 and 36/21 PMR/non-PMR patients, respectively. The cohorts consisted of treatment-naïve patients, who underwent pre-treatment [18F]FDG-PET/CT scans. The [18F]FDG-uptake was then assessed across 34 different anatomical sites. Furthermore, the site-specific [18F]FDG-uptake pattern within each anatomical site was categorized according to its shape. Patients with PMR were more likely than non-PMR patients to have bilateral [18F]FDG-uptake equal to or above liver compared at the ischial tuberosities (91%/41%), shoulder joints (86%/45%), hip joints (83%/52%), and along the lumbar spinal processes (70%/30%). However, a subgroup analysis comparing non-PMR patients with other inflammatory conditions to patients with PMR revealed that several non-PMR patients exhibited a similar whole-body [18F]FDG-uptake pattern. Furthermore, site-specific [18F]FDG-uptake patterns were similar in patients with PMR and non-PMR. Assessing whole-body or site-specific [18F]FDG-uptake patterns does not improve the diagnostic accuracy in distinguishing PMR from other inflammatory diseases. Consequently, [18F]FDG-PET/CT should mainly be used to rule out a clinical diagnosis of PMR. Trial registration: ClinicalTrials.gov (NCT04519580). Registered 17th of August 2020.


  • The effect of prednisolone initiation and short-term discontinuation on the clinical assessment of polymyalgia rheumatica

    by Christoffer S Våben, Andreas W Nielsen, Marc K Nielsen, Line T Moll, Christoffer Mørk, Emil B Dalgaard, Tue K Rasmussen, René D Østgård, Ib T Hansen, Berit D Nielsen, et al.

    Objectives: Approximately half of individuals with suspected PMR initiate prednisolone before rheumatological evaluation, but it is unknown if prednisolone reduces the ability to diagnose PMR. This study evaluated the clinical assessment of a PMR diagnosis before and after prednisolone initiation and after short-term prednisolone discontinuation. Methods: Data from a prospective cohort of treatment-naïve patients with PMR (n = 66) and non-PMR (n = 27) were used to create case report forms (CRFs). All patients were assessed at baseline and patients with PMR were reassessed after 8 weeks of prednisolone treatment (n = 57) and after short-term prednisolone discontinuation at week 10 (n = 48). In total, 198 CRFs were created containing patient demographics, current symptoms, physical examination and blood test results. Six rheumatologists, blinded to diagnosis, prednisolone treatment and visit timing, assessed each CRF, rating the probability of a PMR diagnosis from 0 to 10 and classifying them as PMR or non-PMR. Results: At baseline, CRF assessors effectively distinguished PMR from non-PMR, demonstrating median probabilities of PMR of 7.8 and 2.8, respectively, and a sensitivity/specificity of 85.9%/82.7% for the PMR diagnosis. After prednisolone initiation, the median probability of PMR was 1.0 and sensitivity was 3.5%, followed by a median probability of PMR of 2.3 and a sensitivity of 25% after short-term prednisolone discontinuation. Conclusion: This study shows that clinically assessing PMR becomes challenging after prednisolone initiation, and that short-term prednisolone discontinuation does not improve clinical assessment to pre-treatment levels. Consequently, the study supports recommendations of deferring prednisolone initiation until after specialist evaluation in individuals suspected of having PMR.


  • Comment on: ‘Real-world outcomes of a dedicated fast-track polymyalgia rheumatica clinic’

    by Agnete Overgaard Donskov, Christoffer Søvsø Våben, Elisabeth Lindrup Nielsen, Andreas Wiggers Nielsen, Ellen Margrethe Hauge, Kresten Krarup Keller

  • Low incidence of late-onset giant cell arteritis during the first year in patients with polymyalgia rheumatica–a repeated imaging study

    by Andreas Wiggers Nielsen, Ellen-Margrethe Hauge, Ib Tønder Hansen, Berit Dalsgaard Nielsen, Søren Geill Kjær, Jesper Blegvad, Kate Rewers, Christian Møller Sørensen, Lars Christian Gormsen, Kresten Krarup Keller

    Objective: The objective was to investigate the incidence of late-onset giant cell arteritis (GCA) within the first year in patients diagnosed with polymyalgia rheumatica (PMR). Methods: In this prospective study, treatment-naïve individuals with a new clinical diagnosis of PMR and without GCA symptoms underwent baseline assessments, including vascular ultrasonography and 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography computed tomography (FDG-PET/CT). To prevent biased inclusion, rapid referral clinics were established for all patients suspected of PMR. Additionally, the patients underwent GCA monitoring during clinical visits at weeks 8 and 10, which involved vascular ultrasonography and FDG-PET/CT scans. After one year, a follow-up visit was performed to confirm the PMR diagnosis and perform vascular ultrasonography. Results: A final PMR diagnosis was assigned to 62 patients, excluding two patients with concurrent subclinical GCA and PMR at baseline, corresponding to a baseline prevalence of subclinical GCA of 3%. During the one-year follow-up, two PMR patients developed late-onset GCA corresponding to an incidence rate of 32 per 1000 person-years. One patient developed GCA 14 weeks after the PMR diagnosis, exhibiting cranial symptoms and positive vascular ultrasonography. The other patient presented with subclinical large vessel GCA at the one-year visit detected with vascular ultrasonography and confirmed by FDG-PET/CT. Conclusion: This study is the first to demonstrate a low incidence rate of late-onset GCA in PMR patients within the first year, employing repeated imaging to exclude GCA at baseline and diagnose GCA during follow-up. Additionally, it provides evidence of a low prevalence of subclinical GCA across the entire PMR population. Trial registration: ClinicalTrials.Gov, NCT04519580


  • Improved diagnostic accuracy for polymyalgia rheumatica using FDG-PET/CT with clinical diagnosis or 2012 ACR/EULAR classification criteria

    by Andreas Wiggers Nielsen, Kornelis S M van der Geest, Ib Tønder Hansen, Berit Dalsgaard Nielsen, Søren Geill Kjær, Jesper Blegvad-Nissen, Pieter H Nienhuis, Maria Sandovici, Kate Rewers, Christian Møller Sørensen, et al.

    Objective: In routine care, clinicians may employ 2-[18F]fluoro-2-deoxy-D-glucose (FDG)-PET/CT to validate their initial clinical diagnosis of PMR. Nevertheless, the diagnostic utility of combining FDG-PET/CT findings with clinical presentation has not been explored. Therefore, this study aimed to investigate whether the diagnostic accuracy for PMR could be enhanced by combining FDG-PET/CT findings with the clinical baseline diagnosis or the 2012 ACR/EULAR clinical classification criteria for PMR. Methods: An investigation and a validation cohort were included from two countries, encompassing 66/27 and 36/21 PMR/non-PMR patients, respectively. The cohorts comprised treatment-naïve patients suspected of PMR, who initially received a clinical baseline diagnosis and underwent FDG-PET/CT scans. The FDG-PET/CT Leuven score was applied to classify patients as either PMR or non-PMR and combined with the clinical baseline diagnosis. Final diagnoses were established through clinical follow-up after 12 or six months in the investigation and validation cohorts, respectively. Results: In the investigation cohort, a clinical baseline diagnosis yielded a sensitivity/specificity of 94%/82%, compared with 78%/70% using the ACR/EULAR criteria. Combining the clinical baseline diagnosis with a positive Leuven score showed a sensitivity/specificity of 80%/93%, compared with 80%/82% for an ACR/EULAR-Leuven score. In the validation cohort, the baseline diagnosis revealed a sensitivity/specificity of 100%/91%, compared with 92%/76% using the ACR/EULAR criteria. Combining FDG-PET/CT with the baseline diagnosis demonstrated a sensitivity/specificity of 83%/95% compared with 89%/81% for the ACR/EULAR-Leuven score. Conclusion: Combining FDG-PET/CT findings with the clinical baseline diagnosis or ACR/EULAR clinical classification criteria can improve the diagnostic specificity for PMR.


  • Open Access

    The effect of prednisolone and a short-term prednisolone discontinuation for the diagnostic accuracy of FDG-PET/CT in polymyalgia rheumatica—a prospective study of 101 patients

    by Andreas Wiggers Nielsen, Ib Tønder Hansen, Berit Dalsgaard Nielsen, Søren Geill Kjær, Jesper Blegvad-Nissen, Kate Rewers, Christian Møller Sørensen, Ellen-Margrethe Hauge, Lars Christian Gormsen, Kresten Krarup Keller

    Purpose: 2-[18F]Fluoro-2-deoxy-D-glucose (FDG)–positron emission tomography (PET)/computed tomography (CT) has been suggested as an imaging modality to diagnose polymyalgia rheumatica (PMR). However, the applicability of FDG-PET/CT remains unclear, especially following glucocorticoid administration. This study aimed to investigate the diagnostic accuracy of FDG-PET/CT before and during prednisolone treatment, as well as following short-term prednisolone discontinuation. Methods: Treatment naïve suspected PMR patients were clinically diagnosed at baseline and subsequently had an FDG-PET/CT performed. Patients diagnosed with PMR were administered prednisolone following the first FDG-PET/CT and had a second FDG-PET/CT performed after 8 weeks of treatment. Subsequently, prednisolone was tapered with short-term discontinuation at week 9 followed by a third FDG-PET/CT at week 10. An FDG-PET/CT classification of PMR/non-PMR was applied, utilizing both the validated Leuven score and a dichotomous PMR score. The final diagnosis was based on clinical follow-up after 1 year. Results: A total of 68 and 27 patients received a final clinical diagnosis of PMR or non-PMR. A baseline FDG-PET/CT classified the patients as having PMR with a sensitivity/specificity of 86%/63% (Leuven score) and 82%/70% (dichotomous score). Comparing the subgroup of non-PMR with inflammatory diseases to the PMR group demonstrated a specificity of 39%/54% (Leuven/dichotomous score). After 8 weeks of prednisolone treatment, the sensitivity of FDG-PET/CT decreased to 36%/41% (Leuven/dichotomous score), while a short-term prednisolone discontinuation increased the sensitivity to 66%/60%. Conclusion: FDG-PET/CT has limited diagnostic accuracy for differentiating PMR from other inflammatory diseases. If FDG-PET/CT is intended for diagnostic purposes, prednisolone should be discontinued to enhance diagnostic accuracy. Trial registration: ClinicalTrials.gov (NCT04519580). Registered 17th of August 2020.


  • Recommendations for early referral of individuals with suspected polymyalgia rheumatica: an initiative from the international giant cell arteritis and polymyalgia rheumatica study group

    by Kresten Krarup Keller, Chetan B Mukhtyar, Andreas Wiggers Nielsen, Andrea Katharina Hemmig, Sarah Louise Mackie, Sebastian Eduardo Sattui, Ellen-Margrethe Hauge, Anisha Dua, Toby Helliwell, Lorna Neill, et al.

    Objective To develop international consensus-based recommendations for early referral of individuals with suspected polymyalgia rheumatica (PMR). Methods A task force including 29 rheumatologists/internists, 4 general practitioners, 4 patients and a healthcare professional emerged from the international giant cell arteritis and PMR study group. The task force supplied clinical questions, subsequently transformed into Population, Intervention, Comparator, Outcome format. A systematic literature review was conducted followed by online meetings to formulate and vote on final recommendations. Levels of evidence (LOE) (1–5 scale) and agreement (LOA) (0–10 scale) were evaluated. Results Two overarching principles and five recommendations were developed. LOE was 4–5 and LOA ranged between 8.5 and 9.7. The recommendations suggest that (1) each individual with suspected or recently diagnosed PMR should be considered for specialist evaluation, (2) before referring an individual with suspected PMR to specialist care, a thorough history and clinical examination should be performed and preferably complemented with urgent basic laboratory investigations, (3) individuals with suspected PMR with severe symptoms should be referred for specialist evaluation using rapid access strategies, (4) in individuals with suspected PMR who are referred via rapid access, the commencement of glucocorticoid therapy should be deferred until after specialist evaluation and (5) individuals diagnosed with PMR in specialist care with a good initial response to glucocorticoids and a low risk of glucocorticoid related adverse events can be managed in primary care. Conclusions These are the first international recommendations for referral of individuals with suspected PMR, which complement the European Alliance of Associations for Rheumatology/American College of Rheumatology management guidelines for established PMR.